Table 2.
Prevalence of the clinical and genetic components of the ABCD-GENE score for clopidogrel-treated patients
| Full cohort (n=2341) |
ABCD-GENE <10 (n=1836) |
ABCD-GENE ≥10 (n=505) |
p value for comparison of ABCD-GENE score <10 vs ≥10 | |
|---|---|---|---|---|
| ABCD-GENE Score | 6 [3 – 8] | 4 [3 – 7] | 11 [10 – 13] | <0.001 |
| Age >75 years | 412 (18%) | 239 (13%) | 173 (34%) | <0.001 |
| BMI >30 kg/m2 | 1051 (45%) | 658 (36%) | 393 (78%) | <0.001 |
| CKD | 670 (29%) | 353 (19%) | 317 (63%) | <0.001 |
| Diabetes | 987 (42%) | 641 (35%) | 346 (69%) | <0.001 |
| CYP2C19 Genetic Test | ||||
| 2 LOF alleles (PM) | 20 (1%) | 0 | 20 (4%) | <0.001a |
| 1 LOF allele (IM) | 428 (18%) | 159 (9%) | 269 (53%) | |
| 0 LOF alleles (NM, RM, UM) | 1893 (81%) | 1677 (91%) | 216 (43%) |
a
p value for comparison of ≥1 LOF alleles vs 0 LOF alleles between groups.
Data are presented as median [IQR] or number (%).
BMI, body mass index; CKD, chronic kidney disease defined as an estimated glomerular filtration rate of < 60 ml/min/1.73m2; IM, CYP2C19 intermediate metabolizer; NM, CYP2C19 normal metabolizer; PM, CYP2C19 poor metabolizer; RM, CYP2C19 rapid metabolizer; UM, CYP2C19 ultra-rapid metabolizer; LOF, loss-of-function.